A 38-year-old woman with a history of BRCA1 mutation presents with a 3-month history of progressive abdominal distension, early satiety, and pelvic pain. CA-125 is elevated at 450 U/mL. Imaging reveals a complex adnexal mass with ascites. She undergoes staging laparotomy and is found to have stage IIIC epithelial ovarian cancer. After optimal cytoreductive surgery achieving

Question

A 38-year-old woman with a history of BRCA1 mutation presents with a 3-month history of progressive abdominal distension, early satiety, and pelvic pain. CA-125 is elevated at 450 U/mL. Imaging reveals a complex adnexal mass with ascites. She undergoes staging laparotomy and is found to have stage IIIC epithelial ovarian cancer. After optimal cytoreductive surgery achieving <1 cm residual disease, she receives neoadjuvant platinum-based chemotherapy followed by interval debulking. Which of the following statements regarding her prognosis and treatment is MOST accurate?

Accepted Answer

B. Patients with stage IIIC disease and BRCA1 mutations who achieve optimal cytoreduction and complete response to platinum-taxol chemotherapy have significantly improved progression-free survival and overall survival, and may benefit from PARP inhibitor maintenance therapy. ## Ovarian Cancer Prognosis and Treatment in BRCA1 Mutation Carriers

**Key Point:** BRCA1/BRCA2 mutations confer a significant survival advantage in epithelial ovarian cancer (EOC) through enhanced platinum sensitivity and eligibility for PARP inhibitor maintenance therapy.

### BRCA Status and Prognosis
- **BRCA1/BRCA2-mutant EOC** demonstrates:
  - Superior platinum sensitivity (homologous recombination deficiency)
  - Improved progression-free survival (PFS) with platinum-taxol chemotherapy
  - Improved overall survival (OS) compared to BRCA wild-type tumors
  - Median OS: 50–60+ months vs. 30–40 months in BRCA wild-type

### Stage IIIC Disease Management
- **Optimal cytoreduction** (<1 cm residual) is a major prognostic factor
- **Neoadjuvant chemotherapy followed by interval debulking** is now standard for:
  - Extensive disease (IIIC/IV)
  - Patients deemed unresectable at initial assessment
  - Equivalent or superior outcomes to primary debulking in select populations (CHORUS, EORTC trials)

### PARP Inhibitor Maintenance
- **BRCA1/BRCA2-mutant, platinum-sensitive EOC:**
  - Olaparib (SOLO-1 trial): PFS benefit from 13.8 months → not reached; OS benefit emerging
  - Rucaparib (ARIEL3): PFS improvement in platinum-sensitive recurrence
  - Recommended as standard maintenance post-chemotherapy in BRCA-mutant patients

### Ascites and Staging
- **Ascites alone does NOT define stage IV disease**
- Stage IIIC = peritoneal/omental involvement ± ascites
- Stage IV = pleural effusion, liver parenchymal involvement, or distant metastases
- This patient's ascites is consistent with stage IIIC (peritoneal spread)

**High-Yield:** BRCA-mutant EOC + optimal cytoreduction + platinum response = excellent prognosis with PARP inhibitor maintenance.

Answer

A. BRCA1 mutation status does not influence platinum sensitivity or long-term survival outcomes in epithelial ovarian cancer

Answer

C. Neoadjuvant chemotherapy followed by interval debulking is contraindicated in stage IIIC ovarian cancer because it delays definitive surgery and worsens outcomes compared to primary debulking

Answer

D. The presence of ascites at diagnosis indicates stage IV disease, and prognosis is uniformly poor regardless of cytoreduction quality or chemotherapy response

Explanation

Practice similar questions